A biopharmaceutical company developing prescription therapies for unmet needs in the field of Food Allergy
Location: United States, California, Menlo Park
Employees: 11-50
Phone: +1 650-420-3900
Total raised: $119M
Founded date: 2018
Investors 3
Funding Rounds 1
| Date | Series | Amount | Investors |
| 23.06.2022 | - | $119M | - |
Mentions in press and media 4
| Date | Title | Description |
| 23.06.2022 | Startups and VCs should be preparing for the possibility of stagflation | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox. The last time stagflation hit the U.S., “startup” was a niche term, VC an obscure cottage industr... |
| 22.06.2022 | Alladapt Announces Completion of Oversubscribed $119 Million Institutional Financing | Financing from new and existing investors will support continued development of a novel treatment for food allergy Jim Momtazee and George Montgomery to join Alladapt’s Board of Directors MENLO PARK, Calif., June 22, 2022 (GLOBE NEWSWIRE) -... |
| 22.06.2022 | Alladapt Raises $119 Million to Study Food-Allergy Treatment | Biotechnology startup Alladapt Immunotherapeutics Inc. has raised $119 million in new venture capital to study a drug that could help food-allergy patients avoid severe reactions to tiny amounts of foods like peanuts, eggs and salmon. Food ... |
| 22.06.2022 | Alladapt Announces Completion of Oversubscribed $119 Million Institutional Financing | - |